Delivery Order SPE2DB20D1004-SPE2DB25FNJMR
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,812.82 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 8 mg tablets (30-count packages). This competitively awarded, firm fixed-price contract represents a non-set-aside procurement and carries an ultimate completion date of July 22, 2025. The order will be fulfilled from AmerisourceBergen's operations in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. This delivery order...
- The Defense Logistics Agency awarded a $5,629.86 delivery order to AmerisourceBergen Drug Corp for Ondansetron ODT 4 mg tablets (30-count supply) on July 24, 2025, with an ultimate completion date of July 25, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded through open competition. The place of performance is located in Conshohocken, Pennsylvania, which is also the headquarters location of the prime contractor. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count units) under a firm fixed-price contract valued at $7,389.26. The award was made on July 22, 2025, with an ultimate completion date of July 23, 2025, and represents a non-set-aside competitive award. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location in the same city. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Ondansetron ODT 4 mg tablets (30-count units) with a ceiling value of $8,001.71. This is a firm fixed price, non-competitive delivery order executed under the company's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December 2026. The order will be performed at...
- The Defense Logistics Agency awarded a $7,527.37 delivery order to AmerisourceBergen Drug Corp for Ondansetron ODT 8 mg tablets (30-count supply) on July 22, 2025, with completion scheduled for July 23, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The contract carries no set-aside...
- The Defense Logistics Agency awarded a delivery order valued at $18,060.83 to AmerisourceBergen Drug Corp for the supply of Ondansetron HCL 4 mg tablets (500-count units). This firm fixed-price delivery order, awarded on July 23, 2025, with an ultimate completion date of July 24, 2025, represents a non-set-aside competitive award. The product will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. As a major pharmaceutical distributor and critical vendor...
- The Defense Logistics Agency awarded a delivery order valued at $5,716.47 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 MG tablets in quantities of 30 units. This competitively awarded, firm fixed-price contract is classified as a delivery order with an ultimate completion date of July 25, 2025, one day after the award date of July 24, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. No set-aside designation...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Ondansetron ODT 8 mg tablets in quantities of 30, with a contract ceiling value of $2,831.66. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The contract is scheduled for ultimate completion on July 29, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a $3,276.48 delivery order to AmerisourceBergen Drug Corp for Ondansetron HCL 8 mg tablets (30-count units) on July 28, 2025, with completion targeted for July 29, 2025. This non-set-aside, competitively awarded contract employs firm fixed pricing and represents a delivery order under AmerisourceBergen's larger pharmaceutical supply agreement. The pharmaceutical will be sourced from the vendor's Conshohocken, Pennsylvania facility, where AmerisourceBergen...
- The Defense Logistics Agency awarded a $5,101.23 delivery order to AmerisourceBergen Drug Corp for Ondansetron ODT 4 MG tablets (30-count units) on July 23, 2025, with an ultimate completion date of July 24, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Ondansetron is a widely used antiemetic medication commonly supplied to military and...
- SPE2DB20D1004Indefinite Delivery Contract
- SPE2DB20D1004-SPE2DB25FNJMRDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $8,736.12 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 MG tablets in quantities of 30 units. This competitive award, issued on July 21, 2025, with an ultimate completion date of July 22, 2025, represents a firm fixed-price delivery order with no set-aside designation. The product will be delivered to Conshohocken, Pennsylvania, the location of AmerisourceBergen's corporate headquarters. This delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. As a prime pharmaceutical vendor, AmerisourceBergen supplies a comprehensive range of medications and medical supplies to support military healthcare systems globally. The Ondansetron tablets procured under this delivery order are antiemetic medications commonly used in military and veteran healthcare settings for managing nausea and vomiting associated with chemotherapy, surgery, and radiation therapy.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.7k | 7/21/25 |